Sexual Dysfunction and Emotional Blunting in Women with Major Depressive Disorder on Sertraline: A Pilot Study

Selective serotonin reuptake inhibitors (SSRIs) are widely used for treating major depressive disorder (MDD) but are frequently associated with adverse effects such as sexual dysfunction and emotional blunting. This study aimed to investigate the relationship between sexual dysfunction and emotional blunting in female patients with MDD who were in remission under long-term sertraline therapy. In this pilot study, 22 women in remission from MDD and receiving long-term sertraline treatment were compared to 20 age-matched healthy controls. Participants completed the validated Persian versions of the Female Sexual Function Index (FSFI) and the Laukes Emotional Intensity Scale (LEIS). Between-group comparisons were performed using independent samples t-tests. Pearson correlation analysis was conducted to assess the relationship between sexual function and emotional blunting in the sertraline group. Statistical analysis was conducted using SPSS v26, with significance set at p < 0.05. The total FSFI score was significantly lower in the sertraline group compared with the control group (19.6 ± 4.2 vs. 28.1 ± 3.3; p < 0.001), and 81.8% of patients on sertraline met the criteria for sexual dysfunction, whereas none in the control group did (p < 0.001). Emotional responsiveness was also markedly reduced in the sertraline group (LEIS: 46.36 ± 5.22 vs. 58.95 ± 6.85; p < 0.001). A significant positive correlation was found between total FSFI and LEIS scores (r = 0.76, p < 0.001). These findings suggest a strong relationship between SSRI-induced sexual dysfunction and emotional blunting. Recognizing this overlap is crucial for clinicians managing patients treated with SSRIs. Routine screening for both side effects and personalized treatment strategies may improve patient adherence, quality of life, and overall therapeutic satisfaction. However, these results are specific to women receiving long-term sertraline therapy, and broader generalizations to all SSRI users should be made with caution.